Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Status:
Completed
Trial end date:
2017-03-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well total-body irradiation, donor lymphocyte infusion, and
cyclophosphamide before donor stem cell transplant works in treating patients with high-risk
hematologic malignancies. Giving total-body irradiation, donor lymphocyte infusion, and
chemotherapy before a donor stem cell transplant helps stop the growth of cancer and abnormal
cells and helps stop the patient's immune system from rejecting the donor's stem cells. When
certain stem cells from a donor are infused into the patient they may help the patient's bone
marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells.
Removing the T cells from the donor cells before transplant and giving tacrolimus and
mycophenolate mofetil may stop this from happening.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University